Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
García-Arriaza J, Garaigorta U, Pérez P, Lázaro-Frías A, Zamora C, Gastaminza P, Del Fresno C, Casasnovas JM, Sorzano CÓS, Sancho D, Esteban M. García-Arriaza J, et al. Among authors: garaigorta u. J Virol. 2021 Mar 10;95(7):e02260-20. doi: 10.1128/JVI.02260-20. Epub 2021 Jan 7. J Virol. 2021. PMID: 33414159 Free PMC article.
Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target.
García-Dorival I, Cuesta-Geijo MÁ, Barrado-Gil L, Galindo I, Garaigorta U, Urquiza J, Puerto AD, Campillo NE, Martínez A, Gastaminza P, Gil C, Alonso C. García-Dorival I, et al. Among authors: garaigorta u. Antiviral Res. 2021 Oct;194:105167. doi: 10.1016/j.antiviral.2021.105167. Epub 2021 Aug 24. Antiviral Res. 2021. PMID: 34450201 Free PMC article.
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
Del Fresno C, García-Arriaza J, Martínez-Cano S, Heras-Murillo I, Jarit-Cabanillas A, Amores-Iniesta J, Brandi P, Dunphy G, Suay-Corredera C, Pricolo MR, Vicente N, López-Perrote A, Cabezudo S, González-Corpas A, Llorca O, Alegre-Cebollada J, Garaigorta U, Gastaminza P, Esteban M, Sancho D. Del Fresno C, et al. Among authors: garaigorta u. Front Immunol. 2021 Nov 18;12:748103. doi: 10.3389/fimmu.2021.748103. eCollection 2021. Front Immunol. 2021. PMID: 34867974 Free PMC article.
Effect of Clinically Used Microtubule Targeting Drugs on Viral Infection and Transport Function.
Oliva MÁ, Tosat-Bitrián C, Barrado-Gil L, Bonato F, Galindo I, Garaigorta U, Álvarez-Bernad B, París-Ogáyar R, Lucena-Agell D, Giménez-Abián JF, García-Dorival I, Urquiza J, Gastaminza P, Díaz JF, Palomo V, Alonso C. Oliva MÁ, et al. Among authors: garaigorta u. Int J Mol Sci. 2022 Mar 22;23(7):3448. doi: 10.3390/ijms23073448. Int J Mol Sci. 2022. PMID: 35408808 Free PMC article.
Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron.
Casasnovas JM, Margolles Y, Noriega MA, Guzmán M, Arranz R, Melero R, Casanova M, Corbera JA, Jiménez-de-Oya N, Gastaminza P, Garaigorta U, Saiz JC, Martín-Acebes MÁ, Fernández LÁ. Casasnovas JM, et al. Among authors: garaigorta u. Front Immunol. 2022 Apr 25;13:863831. doi: 10.3389/fimmu.2022.863831. eCollection 2022. Front Immunol. 2022. PMID: 35547740 Free PMC article.
24 results